Characterisation of cell lines derived from prostate cancer patients with localised disease.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
08
09
2021
accepted:
12
05
2023
revised:
17
04
2023
medline:
28
8
2023
pubmed:
2
6
2023
entrez:
1
6
2023
Statut:
ppublish
Résumé
Prostate cancer is a broad-spectrum disease, spanning from indolent to a highly aggressive lethal malignancy. Prostate cancer cell lines are essential tools to understanding the basic features of this malignancy, as well as in identifying novel therapeutic strategies. However, most cell lines routinely used in prostate cancer research are derived from metastatic disease and may not fully elucidate the molecular events underlying the early stages of cancer development and progression. Thus, there is a need for new cell lines derived from localised disease to better span the disease spectrum. Prostatic tissue from the primary site, and adjacent non-cancerous tissue was obtained from four patients with localised disease undergoing radical prostatectomy. Epithelial cell outgrowths were immortalised with human papillomavirus type 16 (HPV16) E6 and E7 to establish monoclonal cell lines. Chromosomal ploidy was imaged and STR profiles were determined. Cell morphology, colony formation and cell proliferation characteristics were assessed. Androgen receptor (AR) expression and AR-responsiveness to androgen treatment were analysed by immunofluorescence and RT-qPCR, respectively. RNA-seq analysis was performed to identify prostate lineage markers and expression of prostate cancer tumorigenesis-related genes. Two benign cell lines derived from non-cancer cells (AQ0420 and AQ0396) and two tumour tissue derived cancer cell lines (AQ0411 and AQ0415) were immortalised from four patients with localised prostatic adenocarcinoma. The cell lines presented an epithelial morphology and a slow to moderate proliferative rate. None of the cell lines formed anchorage independent colonies or displayed AR-responsiveness. Comparative RNA-seq expression analysis confirmed the prostatic lineage of the four cell lines, with a distinct gene expression profile from that of the metastatic prostate cancer cell lines, PC-3 and LNCaP. Comprehensive characterization of these cell lines may provide new in vitro tools that could bridge the current knowledge gap between benign, early-stage and metastatic disease.
Sections du résumé
BACKGROUND
Prostate cancer is a broad-spectrum disease, spanning from indolent to a highly aggressive lethal malignancy. Prostate cancer cell lines are essential tools to understanding the basic features of this malignancy, as well as in identifying novel therapeutic strategies. However, most cell lines routinely used in prostate cancer research are derived from metastatic disease and may not fully elucidate the molecular events underlying the early stages of cancer development and progression. Thus, there is a need for new cell lines derived from localised disease to better span the disease spectrum.
METHODS
Prostatic tissue from the primary site, and adjacent non-cancerous tissue was obtained from four patients with localised disease undergoing radical prostatectomy. Epithelial cell outgrowths were immortalised with human papillomavirus type 16 (HPV16) E6 and E7 to establish monoclonal cell lines. Chromosomal ploidy was imaged and STR profiles were determined. Cell morphology, colony formation and cell proliferation characteristics were assessed. Androgen receptor (AR) expression and AR-responsiveness to androgen treatment were analysed by immunofluorescence and RT-qPCR, respectively. RNA-seq analysis was performed to identify prostate lineage markers and expression of prostate cancer tumorigenesis-related genes.
RESULTS
Two benign cell lines derived from non-cancer cells (AQ0420 and AQ0396) and two tumour tissue derived cancer cell lines (AQ0411 and AQ0415) were immortalised from four patients with localised prostatic adenocarcinoma. The cell lines presented an epithelial morphology and a slow to moderate proliferative rate. None of the cell lines formed anchorage independent colonies or displayed AR-responsiveness. Comparative RNA-seq expression analysis confirmed the prostatic lineage of the four cell lines, with a distinct gene expression profile from that of the metastatic prostate cancer cell lines, PC-3 and LNCaP.
CONCLUSIONS
Comprehensive characterization of these cell lines may provide new in vitro tools that could bridge the current knowledge gap between benign, early-stage and metastatic disease.
Identifiants
pubmed: 37264224
doi: 10.1038/s41391-023-00679-x
pii: 10.1038/s41391-023-00679-x
pmc: PMC10449630
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Receptors, Androgen
0
Androgens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
614-624Informations de copyright
© 2023. The Author(s).
Références
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Oncol Rep. 2016 Apr;35(4):2431-40
pubmed: 26797047
PLoS One. 2018 Jul 20;13(7):e0200613
pubmed: 30028845
Cancers (Basel). 2020 Mar 25;12(4):
pubmed: 32218271
Cancers (Basel). 2020 Sep 17;12(9):
pubmed: 32957478
BMC Cancer. 2017 Jul 11;17(1):480
pubmed: 28697756
Carcinogenesis. 1996 Aug;17(8):1641-6
pubmed: 8761420
Biochim Biophys Acta. 1990 Apr 9;1052(1):187-94
pubmed: 2322591
Endocr Relat Cancer. 2013 Mar 26;20(2):R49-64
pubmed: 23447570
Int J Oncol. 2010 Dec;37(6):1477-82
pubmed: 21042716
Cells. 2019 Jan 20;8(1):
pubmed: 30669516
Int J Cancer. 1997 Dec 10;73(6):910-6
pubmed: 9399675
Nat Rev Urol. 2023 Mar;20(3):158-178
pubmed: 36451039
In Vitro Cell Dev Biol Anim. 2006 Sep-Oct;42(8-9):273-80
pubmed: 17163777
Int J Cell Biol. 2012;2012:306879
pubmed: 22505926
Arch Med Sci. 2018 Jun;14(4):910-919
pubmed: 30002710
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Prostate. 2017 Dec;77(16):1563-1572
pubmed: 28971496
Front Mol Biosci. 2020 Mar 06;7:33
pubmed: 32211418
Endocr Relat Cancer. 2013 Jun 24;20(4):R155-70
pubmed: 23580590
Neoplasia. 2002 Jan-Feb;4(1):19-31
pubmed: 11922387
Nucleic Acids Res. 2019 Jan 8;47(D1):D590-D595
pubmed: 30321428
Prostate. 2008 Jun 15;68(9):1025-34
pubmed: 18386293
Cancer Res. 2006 Apr 1;66(7):3531-40
pubmed: 16585177
Nature. 2013 Sep 19;501(7467):338-45
pubmed: 24048066
Prostate. 2017 Oct;77(14):1389-1400
pubmed: 28845520
Anticancer Res. 2005 Jan-Feb;25(1A):1-8
pubmed: 15816512
Sci Rep. 2019 Jul 5;9(1):9776
pubmed: 31278310
Prostate Cancer Prostatic Dis. 2021 Mar;24(1):233-243
pubmed: 32873916
Int J Cancer. 2020 Mar 1;146(5):1346-1358
pubmed: 31241767
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Prostate. 1999 Aug 1;40(3):150-8
pubmed: 10398276
Biol Chem. 2014 Sep;395(9):1127-32
pubmed: 25153393
Prostate. 2020 May;80(6):491-499
pubmed: 32068909
Invest Urol. 1979 Jul;17(1):16-23
pubmed: 447482
Stem Cell Res Ther. 2017 Apr 26;8(1):95
pubmed: 28446230
Int J Cancer. 1978 Mar 15;21(3):274-81
pubmed: 631930
Oncotarget. 2018 May 29;9(41):26291-26298
pubmed: 29899859
Sci Rep. 2019 Sep 19;9(1):13579
pubmed: 31537872
Bioinformatics. 2012 Nov 1;28(21):2782-8
pubmed: 22923299
Genome Biol. 2010;11(3):R25
pubmed: 20196867
Prog Clin Biol Res. 1980;37:115-32
pubmed: 7384082
J Biol Methods. 2015;2(1):
pubmed: 26146646
Nat Cancer. 2022 Feb;3(2):232-250
pubmed: 35221336
Tissue Eng Part A. 2009 Mar;15(3):559-67
pubmed: 18724832
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
PLoS One. 2008;3(10):e3368
pubmed: 18852876
J Urol. 2005 Feb;173(2):342-59
pubmed: 15643172
Prostate. 1996 Dec;29(6):386-94
pubmed: 8977636
Cancer Res. 1994 Nov 1;54(21):5579-83
pubmed: 7923200
Genome Res. 2002 Jun;12(6):996-1006
pubmed: 12045153
Biomed Res Int. 2020 Sep 24;2020:5395312
pubmed: 33029516
Adv Exp Med Biol. 2019;1164:109-118
pubmed: 31576544
BMC Med Genomics. 2008 Aug 07;1:34
pubmed: 18687136
Nat Genet. 2021 Aug;53(8):1187-1195
pubmed: 34211178
Carcinogenesis. 1997 Jun;18(6):1215-23
pubmed: 9214605
Nat Commun. 2017 Oct 20;8(1):1077
pubmed: 29057876
J Pathol. 2012 Jan;226(2):380-93
pubmed: 21953325
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
BMC Bioinformatics. 2014;15 Suppl 2:S2
pubmed: 24564555
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
J Urol. 2005 Feb;173(2):360-72
pubmed: 15643173
Cell Rep. 2022 Jul 26;40(4):111123
pubmed: 35905714
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Cancers (Basel). 2021 Feb 22;13(4):
pubmed: 33671614
In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24
pubmed: 7535634
Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40
pubmed: 9465086
Sci Rep. 2015 Oct 20;5:15377
pubmed: 26483214
Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11874-8
pubmed: 7991549